Medicines New Zealand updates its code of practice to cover social media

13 August 2014
new-zealand

New Zealand's pharmaceutical industry association, Medicines New Zealand, has updated its Code of Practice in pursuit of keeping standards high for the industry.

The code is reviewed and updated every three years to remain in touch with legislation and industry standards. The review of the code resulted in changes including strengethening the information on social media, updating advertising sections to align with changes to the Medicines Amendment Regulations 2011 and providing information on online advertisements.

It has also strengthened and added new sections on interactions and relationships with the general public, patients and patient organisations, with further changes made to the section on media releases, Product Familiarization Programs, company-commissioned articles, external meeting sponsorship, and items of medical utility. There is also now provision for a fee waiver for complaints from members of the public in certain circumstances.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical